Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
Official title: Immune Tolerance Network
Funded at Benaroya Research Inst at Virginia Mason · NIH-11609235 · Data updated 2026-11-12
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 1, 2014 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $427,401 |
| NIH project number | 3UM1AI109565-13S1 |
| Project ID | NIH-11609235 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with autoimmune diseases, allergies, or conditions involving immune system malfunction who may be eligible for tolerance-based therapies within network trials.
✕Less likely to help
People without immune-related conditions or who do not meet trial eligibility may not benefit from these specific tolerance therapies.
What this research studies
The ITN brings together many doctors and researchers to test new treatments that teach the immune system to tolerate certain tissues or reduce harmful immune reactions. It combines clinical trials with advanced lab analyses to understand how the therapies work at cellular and genetic levels. The goal is to move promising tolerance therapies into practice more quickly while learning across different diseases. This program is designed to adapt and evolve as new scientific ideas emerge and as successful strategies are identified. It partners with many clinical sites and researchers to advance options for patients who struggle with immune-related conditions.
Why it matters
Potential benefit: If successful, this research could lead to safer, more effective ways to prevent immune rejection and reduce autoimmune or allergic disease activity.
How similar studies have gone: Previous tolerance-focused trials have shown potential, but this program emphasizes ongoing innovation and cross-disease learning to accelerate translation.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.